<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04727489</url>
  </required_header>
  <id_info>
    <org_study_id>C16-89</org_study_id>
    <nct_id>NCT04727489</nct_id>
  </id_info>
  <brief_title>Study of the Genetic Factors Involved in Autism and Related Disorders</brief_title>
  <acronym>Gene&amp;autism</acronym>
  <official_title>Study of the Genetic Factors Involved in Autism and Related Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to define, for Autism Spectrum Disorder, the extent of&#xD;
      genetic variation in synaptic pathways that may be targeted for therapeutic development. For&#xD;
      this purpose the investigators will take advantage of large, well-characterized cohorts of&#xD;
      patients with Autism Spectrum Disorder for genetic screenings. Targeted sequencing of&#xD;
      selected synaptic genes, previously associated with Autism Spectrum Disorder, will be carried&#xD;
      out in these cohorts with deep coverage of coding regions and a strong focus on previously&#xD;
      untested regulatory regions. Genomic data from Copy Number Variant, whole genome sequencing&#xD;
      and exome sequencing, available for some of these patients, will be integrated in the overall&#xD;
      analysis. The investigators will strongly emphasize the establishment of comprehensive&#xD;
      genotype/phenotype correlations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim 1: To identify genetic variants in selected synaptic genes, by targeted sequencing with&#xD;
      deep coverage of coding regions and a strong focus on previously untested regulatory regions&#xD;
      in Autism Spectrum Disorder&#xD;
&#xD;
      Aim 2: To define the range of clinical phenotypes caused by mutations in synaptic genes by&#xD;
      establishing detailed genotype/phenotype correlations and analyzing segregation in families&#xD;
      with multiple individuals affected by Autism Spectrum Disorder, Autism Spectrum Disorder&#xD;
      traits or other neuropsychiatric disorders&#xD;
&#xD;
      Aim 3: To identify the neuronal phenotypes caused by deleterious synaptic mutations for&#xD;
      further translational studies&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2037</completion_date>
  <primary_completion_date type="Anticipated">December 21, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of synaptic gene deleterious mutations in patients with Autism Spectrum Disorder</measure>
    <time_frame>up to 12 months after completion of the inclusion and molecular explorations</time_frame>
    <description>Prevalence of synaptic gene deleterious mutations in patients with Autism Spectrum Disorder</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of the deleterious mutations in the major biological pathways in Autism Spectrum Disorder</measure>
    <time_frame>up to 12 months after completion of the inclusion and molecular explorations</time_frame>
    <description>The deleterious mutations that the investigators will identify in genes related to Autism Spectrum Disorders will help to have a comprehensive framework of biological pathways involved in Autism Spectrum Disorder</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">3800</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Autism Spectrum Disorder</arm_group_label>
    <description>Probands with Autism Spectrum Disorder, (N=700), Diagnosis of ASD according to DSM-V criteria For all patients included in the study, core assessment carried out by either collaborating partners consists of diagnosis using the Autism Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders. Patients with profound intellectual disability or with a known medical cause of autism, such as neurocutaneous syndromes, Fragile X, metabolic disorders, extreme prematurity, congenital rubella and other prenatal or postnatal neurological infections or gross dysmorphology, will be excluded.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control without Autism Spectrum Disorder</arm_group_label>
    <description>Controls without Austim Spectrum Disorder, aged 6 to 40, N=2100 (300 adultes, 300 children) Healthy individuals with or without idiopathic surgical or urological conditions (e.g. orthopaedic conditions, hernia repairs, renal malformations, pre- or post-circumcision, phimosis, balanitis, scoliosis, congenital hip dislocation, adenoid or tonsil removal, dental procedures such as wisdom tooth extraction, cosmetic procedures such as removal of skin tags or cleft lip repairs, non-head injuries such as fractures, drainage of subungual or perichondrial haematomata).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Relatives of probands with Autism Spectrum Disorder</arm_group_label>
    <description>Relatives of probands with Autism Spectrum Disorder (N=1200 parents, N=600 siblings, N=300 other relatives)&#xD;
Without Autism Spectrum Disorder diagnosis according to DSM-V,&#xD;
With Autism Spectrum Disorder diagnosis according to DSM-V, and using the Autism Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Relatives of controls</arm_group_label>
    <description>Relatives of controls without Autism Spectrum Disorder, N=400 first degree relatives</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA from subjects will be stored in the biobank of our study.</intervention_name>
    <description>Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders.</description>
    <arm_group_label>Autism Spectrum Disorder</arm_group_label>
    <arm_group_label>Control without Autism Spectrum Disorder</arm_group_label>
    <arm_group_label>Relatives of controls</arm_group_label>
    <arm_group_label>Relatives of probands with Autism Spectrum Disorder</arm_group_label>
    <other_name>diagnostic test</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA from subjects will be stored in the biobank of our study. From some patients with&#xD;
      deleterious mutations in synaptic genes,&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        For all patients included in the study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion&#xD;
        Criteria-----------------------------------------------------------------------------------&#xD;
        ----------------&#xD;
&#xD;
        Probands with Autism Spectrum Disorder&#xD;
&#xD;
          -  Meet the diagnostic criteria for ASD of the DSM-5 [American Psychiatric Association,&#xD;
             2013] based on a consensus between the clinical expertise of expert clinicians, the&#xD;
             scores of the Autism Diagnostic Interview-Revised (ADI-R) (Rutter et al, 2003) and&#xD;
             those of the Autism Diagnosis Observation Schedule (ADOS-2) (Lord et al, 2012)&#xD;
&#xD;
          -  Be at least 24 months (no upper age limit)&#xD;
&#xD;
          -  Somatic and Intellectual state compatible with a blood test&#xD;
&#xD;
          -  Affiliation to the social insurance&#xD;
&#xD;
          -  Signature of informed consent by the applicant or by holders of parental authority if&#xD;
             the subject is a minor or by the guardian if the subject is under guardianship&#xD;
&#xD;
        Controls without ASD&#xD;
&#xD;
          -  At least 24 months old&#xD;
&#xD;
          -  Somatic and Intellectual state compatible with a blood test&#xD;
&#xD;
          -  Affiliation to the social insurance&#xD;
&#xD;
          -  Signature of informed consent by the subject or by holders of parental authority if&#xD;
             the subject is a minor or by the guardian if the subject is under guardianship&#xD;
&#xD;
        Relatives of the probands with ASD or of controls without ASD&#xD;
&#xD;
          -  At least 24 months old&#xD;
&#xD;
          -  Somatic and Intellectual state compatible with a blood test&#xD;
&#xD;
          -  Affiliation to the social insurance&#xD;
&#xD;
          -  Signature of informed consent by the subject or by holders of parental authority if&#xD;
             the subject is a minor or by the guardian if the subject is under guardianship&#xD;
&#xD;
        Exclusion Criteria&#xD;
        -------------------------------------------------------------------------------------------&#xD;
        -------&#xD;
&#xD;
        Probands with Autism Spectrum Disorder&#xD;
&#xD;
          -  Severe Intelectual Deficiency (IQ,35 or developmental age &lt;18 months)&#xD;
&#xD;
             ●. Personal psychiatric history (schizophrenia, bipolar disorder, substance use&#xD;
             disorder (except tobacco), recurrent depression disorder, severe instable anxiety&#xD;
             disorder)&#xD;
&#xD;
          -  Personal neurologic history (epilepsy, or severe neurological disease)&#xD;
&#xD;
        Relatives of the probands with ASD, of the controls or the controls:&#xD;
&#xD;
        ● Medical condition (psychiatric or somatic) not compatible with the inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Months</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Richard Delorme, M.D, Ph.D</last_name>
    <phone>+0033662725334</phone>
    <email>richard.delorme@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Albert Chenevier Hospital</name>
      <address>
        <city>Creteil</city>
        <state>Ile De France</state>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marion Leboyer, MD., PhD.</last_name>
      <phone>+33 (0)1 49 81 32 90</phone>
      <email>marion.leboyer@inserm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Robert Debré Hospital</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>richard delorme, MD., PhD.</last_name>
      <phone>+33 (0)6 62 72 53 34</phone>
      <email>richard.delorme@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>richard Delorme, M.D,Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CIC, CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Fayon, MD., PhD.</last_name>
      <phone>+33 (0)5 57 82 01 08</phone>
      <email>michael.fayon@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CRA, Hopital Charles Perrens, Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauel Bouvard, MD., PhD.</last_name>
      <phone>+33 (0)5 56 56 17 19</phone>
      <email>bouvard.manuel@wanadoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIC, H. Mondor, Creteil</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe Le Corvoisier, MD., PhD.</last_name>
      <phone>+33 (0)1 49 81 37 96</phone>
      <email>philippe.lecorvoisier@inserm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de rehabilitation psychosociale, Hopital Saint Egreve</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julien Dubreucq, MD.</last_name>
      <phone>+33 (0)4 76 56 44 40</phone>
      <email>jdubreucq@ch-alpes-isere.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.inserm.fr</url>
    <description>Description website of the sponsor</description>
  </link>
  <results_reference>
    <citation>Delorme R, Ey E, Toro R, Leboyer M, Gillberg C, Bourgeron T. Progress toward treatments for synaptic defects in autism. Nat Med. 2013 Jun;19(6):685-94. doi: 10.1038/nm.3193. Epub 2013 Jun 6. Review.</citation>
    <PMID>23744158</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 20, 2021</study_first_submitted>
  <study_first_submitted_qc>January 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>autism</keyword>
  <keyword>developmental Disorder</keyword>
  <keyword>gene</keyword>
  <keyword>polymorphism</keyword>
  <keyword>mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://www.inserm.fr</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>http://www.inserm.fr</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

